Q2 FY2026 EarningsQ2 FY26 results missed consensus on the bottom line, with a GAAP EPS of -$0.49 vs. -$0.39 expected. As a clinical-stage biopharmaceutical company, revenue remained at $0.0, in-line with expectations. The net loss widened to $32.5M compared to the $26.5M expected, primarily driven by a surge in R&D internal expenses including $9.4M in stock-based compensation. Despite the earnings miss, the company strengthened its liquidity significantly through a $460M public offering in June 2026, ending the quarter with $895.2M in cash and marketable securities.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Enliven Therapeutics(ELVN) the EBIT is -37.21 M (-30.17%), Miss estimate;the EPS is -0.49 (+0%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.04B30.17%
-0.03B7.38%
-0.01B22.79%
EPSMiss expectations
-0.49--
-0.395719.24%
-0.094319.24%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf